Grace Therapeutics is reporting its QQ1 2026 results with no revenue yet and a substantive operating loss driven by ongoing R&D and commercialization preparations. The quarter shows an EBITDA of -3.36 million and net income of -3.362 million, translating into an EPS of -0.21 on 15.9 million weighted average shares. With cash and cash equivalents of $20.0 million and a net cash position of -$20.0 million (i.e., net cash), the company maintains a meaningful liquidity runway while continuing to fund its pipeline activities. The balance sheet is heavily weighted by intangible assets and goodwill, reflecting pipeline and potential acquisition-related value, which implies heightened impairment and milestone-risk scrutiny but also potential upside if late-stage program milestones are achieved.
Key Performance Indicators
Operating Income
Increasing
-3.09M
QoQ: 16.58% | YoY: 5.30%
Net Income
Decreasing
-3.36M
QoQ: 19.09% | YoY: -6.19%
EPS
Increasing
-0.21
QoQ: 41.67% | YoY: 38.24%
Revenue Trend
Margin Analysis
Financial Highlights
Revenue: Not applicable/not reported for QQ1 2026. YoY/QoQ revenue data is not available.
Gross Profit: -$2,000 (cost of revenue $2,000 with no associated revenue).
Operating Income: -$3.090 million for QQ1 2026; YoY growth estimated at 5.30% vs prior period, QoQ growth of 16.58% per disclosed metrics, reflecting modest sequential improvement in operating loss as some cost bases evolve.
EBITDA: -$3.360 million; EBITDA margin not meaningful given no revenue.
Net Income: -$3.362 million; YoY change -6.19%, QoQ change +19.09% (reflecting a tighter loss vs the prior quarter on a net basis).
EPS (Diluted): -$0.21; YoY +38.24%, QoQ +41.67%.
Cash Flow: Net cash used in operating activities -$1.801 million; Free cash flow -$1.801 million.
Liquidity: Cash and cash equivalents $20.005 million; Net debt = -$20.005 million (net cash position).
Balance Sheet Health: Total assets $69.805 million; total liabilities $6.255 million; total stockholders’ equity $63.550 million. Intangibles and goodwill amount to $49.266 million, constituting ~70% of total assets, indicating a pipeline- or acquisition-derived asset base with impairment risk potential.
Capital Structure: No long-term debt reported; net cash position provides runway for continued R&D investment given current burn rates.
Income Statement
Metric
Value
YoY Change
QoQ Change
Gross Profit
-2.00K
N/A
N/A
Operating Income
-3.09M
5.30%
16.58%
Net Income
-3.36M
-6.19%
19.09%
EPS
-0.21
38.24%
41.67%
Key Financial Ratios
Management Insights Available for Members
Get exclusive access to management commentary, earnings call quotes, and forward guidance from company leadership.